At a glance
ClinicalIndex Comparison RecordN/ACompleted· 17 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of an Oral Antioxidant, N-Acetyl-L-Cysteine, on Inflammatory and Oxidative Stress Markers in Pulmonary Sarcoidosis
In Brief
A clinical study evaluating N-acetyl-cysteine and Placebo for Pulmonary Sarcoidosis. Completed, enrolled 17 participants across 1 site.
Detailed Summary
This is a pilot study investigating the effect of an antioxidant, N-Acetyl-L-Cysteine (NAC), on inflammation and oxidative stress in sarcoidosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Sarcoidosis
CountriesUnited States
CollaboratorsAmerican Thoracic Society
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2011
First PostedApr 2012
Primary CompletionOct 2014
TodayJul 2026
First PostedApr 27, 2012
Enrollment StartNov 1, 2011
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 14.2 years ago
Interventions
N-acetyl-cysteinedietary
900mg three times daily for 8 weeks
Placebodrug
Matching placebo three times daily for 8 weeks.